Abstract
Customized chemotherapy is increasingly used in the management of patients with advanced non-small cell lung cancer (NSCLC). However, the most reliable methodology to determine biomarker status is neither fully elucidated nor agreed upon. Accordingly, we evaluated the predictive efficiency of qRT-PCR and immunohistochemical analysis (IHC) on excision cross complementation group 1 (ERCC1), breast cancer susceptibility gene 1 (BRCA1), ribonucleotide reductase subunit M1 (RRM1) and class III β-tubulin (TUBB3).
| Original language | English |
|---|---|
| Journal | Lung Cancer |
| Volume | 75 |
| Issue number | 3 |
| Pages (from-to) | 306-12 |
| Number of pages | 7 |
| ISSN | 0169-5002 |
| DOIs | |
| Publication status | Published - 2012 |
Fingerprint
Dive into the research topics of 'RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS